Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying older adults aged 75 years and older with advanced chronic kidney disease to find out which educational program better supports their kidney therapy decision-making. The study also aims to see if either program can reduce hospital and emergency room visits within the first six months and possibly improve end-of-life care for these patients. This research explores the first palliative care intervention integrated into routine nephrology care to help patients express their treatment preferences and address unanswered questions. Participants will be randomly assigned to one of two programs. Program A includes information from the National Kidney Foundation and meetings with a kidney therapy educator. Program B offers a video and paper decision aid along with coaching from a decision-support specialist who helps with kidney therapy decisions. Both programs focus on supporting patients in making informed choices about their treatment. During the study, participants decision-making process will be assessed at baseline, 4 to 6 weeks, and 12 weeks using the Decisional Conflict Scale. Researchers will also track changes in patients well-being, hospital admissions, intensive care admissions, emergency room visits, and end-of-life care over six months. The study includes surveys and verbal assessments, and participants progress will be monitored to understand the impact of each program on their care and treatment choices.
Actively Recruiting
Researchers are evaluating treatments for patients with advanced head and neck cancer that has spread locally or to distant parts and who cannot receive cisplatin. This phase III trial compares two approaches combined with intensity modulated radiation therapy IMRT cetuximab, a monoclonal antibody targeting EGFR on cancer cells, versus chemotherapy with carboplatin and paclitaxel. The study aims to determine which treatment better controls the cancer and improves survival while considering safety and quality of life. Participants are randomly assigned to one of two groups. One group receives IMRT five days per week for 35 treatments alongside cetuximab given intravenously as a loading dose before radiation and then weekly concurrent infusions for seven cycles. The other group receives the same IMRT schedule with weekly intravenous carboplatin and paclitaxel for seven cycles during radiation. Both groups undergo imaging scans like CT, MRI, or PETCT during screening and follow-up, as well as blood sample collections throughout the study. Participants are followed after treatment completion at 30 days, then at 4, 6, 12, 18, 24, 30, and 36 months, and annually thereafter. Researchers collect data on cancer progression, survival, treatment side effects, and changes in diet, eating, and speech. The main outcome measured is progression-free survival up to eight years, with additional monitoring of overall survival, adverse events, patterns of cancer recurrence, and quality of life changes over time.
Actively Recruiting
Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating radiation therapy options for men with high-risk prostate cancer in this phase III trial. The study compares a shorter course of stereotactic body radiation therapy SBRT, which delivers five high-dose treatments over two weeks, to the usual longer radiation therapy given over 4 to 9 weeks. The goal is to see if the shorter treatment is as effective in preventing cancer from returning as the standard therapy. Participants are randomly assigned to one of two groups the first group receives SBRT with five treatments over two weeks, and the second group undergoes external beam radiation therapy EBRT with 20 to 45 treatments over 4 to 9 weeks. Both groups may have bone scans, CT, MRI, or PETCT scans during screening and on study, and they may optionally provide blood and urine samples. This trial includes follow-up visits every six months for five years to monitor outcomes. During the study, participants will have various assessments including imaging and questionnaires to evaluate urinary, bowel, sexual function, fatigue, quality of life, and treatment burden. Researchers will track metastasis-free survival, failure-free survival, overall survival, adverse events, and patient-reported outcomes up to 15 years. The study aims to provide detailed information about the effectiveness and impact of the shorter radiation therapy compared to the usual treatment.
Actively Recruiting
Researchers are evaluating the addition of stereotactic body radiation therapy SBRT to the usual treatment for patients with locally advanced, inoperable non-small cell lung cancer that has spread to nearby tissue or lymph nodes. This phase III trial compares the effect of SBRT combined with conventional image guided radiation therapy IGRT, chemotherapy, and subsequent immunotherapy or targeted therapy to the usual treatment alone. The goal is to see if adding SBRT improves overall survival and progression-free survival. Participants are randomly assigned to one of two groups. Arm I receives conventional IGRT with chemotherapy regimens including paclitaxel, carboplatin, pemetrexed, cisplatin, or etoposide during radiotherapy, followed by consolidation immunotherapy with durvalumab or targeted therapy with osimertinib. Arm II receives SBRT to the primary tumor plus conventional IGRT to nodal metastases along with the same chemotherapy and consolidation treatments. Imaging with CT or PETCT scans is used during follow-up. During the study, participants undergo regular assessments including scans and pulmonary function tests at baseline and at 6 and 12 months after radiation therapy. Researchers also collect patient-reported outcomes and monitor quality of life, adverse events, and changes in lung function over time. Biospecimens and advanced imaging data are collected for further analysis. Participants are followed every 3 months for the first year, then every 6 months for years 2 and 3, and yearly thereafter, for up to 13 years total.